Actuate Therapeutics Inc

NASDAQ:ACTU

Biotechnology

Healthcare
$2.09 +2.96%

+$0.06 today

Market cap
$50.01M
Beta
0.53
P/E (TTM)
-2.3
EPS (TTM)
-$0.92
52W Low $1.58High $9.22

Volume 0.03M

Average 0.16M

ACTU Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Actuate Therapeutics IncNASDAQ: ACTU

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 109.1% from a year ago

Cash & equivalents stood at $8.13M at the end of Q1 FY2026, up 109.1% from a year earlier and down 38.2% from the prior quarter. Over 3 fiscal years it compounded at -13.7% a year.

Context

  • Cash & equivalents amounted to 91.3% of total assets at the end of Q1 FY2026, up 4.5 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +109.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.13M-38.2% QoQ
Last fiscal yearDec 2025
$13.16M+52.3% YoY
Year agoMar 2025
$3.89M+109.1% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+109.1%——
1 year+52.3%——
3-year CAGR-13.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
13.16M USD
Year-over-year change
+52.3%
3-year CAGR
-13.7%

Cash & Equivalents vs competitors

How ACTU compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +109.1% is the 2nd highest of 9, against a peer median of -3.4%.
  • Cash & equivalents amounts to 91.3% of total assets for ACTU, versus a peer median of 32.8%.
ACTU Competitors
Cash & Equivalents for ACTU and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VORVor Biopharma Inc.Mar 2026$169.87M USD+239.4%+90.1%33.5%
MOLNMolecular Partners AGMar 2026CHF 78.53M CHF-3.5%-2.0%89.9%
ALECAlector, Inc.Mar 2026$76.96M USD+102.7%-24.7%32.1%
SPROSpero Therapeutics, Inc.Mar 2026$56.13M USD+14.8%-28.3%95.1%
PEPGPepGen Inc.Mar 2026$42.15M USD-3.4%-30.7%27.0%
MCRBSeres Therapeutics, Inc.Mar 2026$29.83M USD-49.3%-34.5%25.4%
NKTXNkarta, Inc.Mar 2026$27.36M USD-48.0%+1.9%7.4%
ELTXElicio Therapeutics, Inc.Mar 2026$14.95M USD-18.5%+33.5%65.9%
ACTUActuate Therapeutics IncMar 2026$8.13M USD+109.1%-13.7%91.3%
Peer median (excluding ACTU) —-3.4%-13.4%32.8%

Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents20.45M2.96M8.64M13.16M
Short-term Investments0000
Net Receivables0000
Inventory0000
Other Current Assets33.75K36.91K0484K
Total Current Assets20.48M3M9.21M13.64M
Property, Plant & Equipment (Net)0000
Goodwill0000
Intangible Assets0000
Long-term Investments0000
Tax Assets0000
Other Non-current Assets00110.55K392.49K
Total Non-current Assets00110.55K392.49K
Total Assets20.48M3M9.32M14.04M
Account Payables2.13M3.42M1.92M1.52M
Short-term Debt0000
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities2.08M277.5K03.59M
Total Current Liabilities4.34M6.92M8.8M5.71M
Long-term Debt404.99K00404.99K
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities900.76K95.7M411.76K0
Total Non-current Liabilities1.31M95.7M411.76K404.99K
Total Liabilities5.65M102.62M9.21M6.11M
Common Stock322023
Retained Earnings(80.35M)(105.09M)(132.38M)(154.61M)
Accumulated OCI0(0)00
Other Stockholders Equity01(834)0
Minority Interest0000
Total Equity14.83M(99.63M)104.19K7.92M
Total Debt404.99K00404.99K
Net Debt(20.04M)(2.96M)(8.64M)(12.75M)

Actuate Therapeutics Inc

NASDAQ:ACTU

Intrinsic Alpha fair value

Locked

Current Price

$2.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.